Cargando…
The nature of relapse in schizophrenia
BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855/ https://www.ncbi.nlm.nih.gov/pubmed/23394123 http://dx.doi.org/10.1186/1471-244X-13-50 |
_version_ | 1782475546096041984 |
---|---|
author | Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Harvey, Brian H |
author_facet | Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Harvey, Brian H |
author_sort | Emsley, Robin |
collection | PubMed |
description | BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the nature and underlying neurobiology of relapse. RESULTS: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis. CONCLUSIONS: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered. |
format | Online Article Text |
id | pubmed-3599855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35998552013-03-17 The nature of relapse in schizophrenia Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Harvey, Brian H BMC Psychiatry Review BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the nature and underlying neurobiology of relapse. RESULTS: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis. CONCLUSIONS: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered. BioMed Central 2013-02-08 /pmc/articles/PMC3599855/ /pubmed/23394123 http://dx.doi.org/10.1186/1471-244X-13-50 Text en Copyright ©2013 Emsley et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Harvey, Brian H The nature of relapse in schizophrenia |
title | The nature of relapse in schizophrenia |
title_full | The nature of relapse in schizophrenia |
title_fullStr | The nature of relapse in schizophrenia |
title_full_unstemmed | The nature of relapse in schizophrenia |
title_short | The nature of relapse in schizophrenia |
title_sort | nature of relapse in schizophrenia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855/ https://www.ncbi.nlm.nih.gov/pubmed/23394123 http://dx.doi.org/10.1186/1471-244X-13-50 |
work_keys_str_mv | AT emsleyrobin thenatureofrelapseinschizophrenia AT chilizabonginkosi thenatureofrelapseinschizophrenia AT asmallaila thenatureofrelapseinschizophrenia AT harveybrianh thenatureofrelapseinschizophrenia AT emsleyrobin natureofrelapseinschizophrenia AT chilizabonginkosi natureofrelapseinschizophrenia AT asmallaila natureofrelapseinschizophrenia AT harveybrianh natureofrelapseinschizophrenia |